Avalon GloboCare Regains Compliance with Nasdaq Stockholders’ Equity Requirement, Launches Marketing for Automated Generative AI Video Platform

Core Viewpoint - Avalon GloboCare Corp. has regained compliance with Nasdaq's minimum stockholders' equity requirement, allowing its common stock to continue being listed and traded on the Nasdaq Capital Market [1][2][3] Company Overview - Avalon GloboCare Corp. is a diversified company focused on developing precision diagnostic consumer products and advancing intellectual property in cellular therapy and generative AI publishing and software [4] - The company is currently marketing the KetoAir™ breathalyzer device, which is registered with the U.S. FDA as a Class I medical device, and plans to develop additional diagnostic uses for this technology [4] Financial Position - The company has made progress in strengthening its financial position, which is reflected in its regained compliance with Nasdaq's requirements [3] - The cancellation of the previously scheduled hearing before the Nasdaq Hearings Panel indicates a positive development for the company's stock listing status [2] Growth Initiatives - With full Nasdaq compliance restored, the company is positioned to execute growth initiatives, including launching marketing for its generative AI video platform and expanding its precision diagnostics and strategic assets [3]